image credit: Freepik

TriLink BioTechnologies to Expand Manufacturing Capabilities

TriLink BioTechnologies announced the expansion of its messenger RNA (mRNA) manufacturing capabilities on May 24, 2023. The new construction of the current good manufacturing practice (CGMP)-grade facility will help the company with its mission to advance the field as more mRNA-based therapeutics and vaccines enter later-stage clinical trials, according to the company press release.

Further, the new CGMP facility is expected to contribute to the development of mRNA therapeutics, with a building designed for the CGMP manufacture of mRNA-based in-vivo gene editing, gene-edited cell therapies, protein replacement therapies, cancer vaccines, and infectious disease vaccines.

Read More on Biopharm International